How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review

Jenny A Doust, Eva Pietrzak, Annette Dobson, Paul Glasziou

Research output: Contribution to journalReview articleResearchpeer-review

526 Citations (Scopus)

Abstract

OBJECTIVE: To assess how well B-type natriuretic peptide (BNP) predicts prognosis in patients with heart failure.

DESIGN: Systematic review of studies assessing BNP for prognosis in patients with heart failure or asymptomatic patients.

DATA SOURCES: Electronic searches of Medline and Embase from January 1994 to March 2004 and reference lists of included studies.

STUDY SELECTION AND DATA EXTRACTION: We included all studies that estimated the relation between BNP measurement and the risk of death, cardiac death, sudden death, or cardiovascular event in patients with heart failure or asymptomatic patients, including initial values and changes in values in response to treatment. Multivariable models that included both BNP and left ventricular ejection fraction as predictors were used to compare the prognostic value of each variable. Two reviewers independently selected studies and extracted data.

DATA SYNTHESIS: 19 studies used BNP to estimate the relative risk of death or cardiovascular events in heart failure patients and five studies in asymptomatic patients. In heart failure patients, each 100 pg/ml increase was associated with a 35% increase in the relative risk of death. BNP was used in 35 multivariable models of prognosis. In nine of the models, it was the only variable to reach significance-that is, other variables contained no prognostic information beyond that of BNP. Even allowing for the scale of the variables, it seems to be a strong indicator of risk.

CONCLUSION: Although systematic reviews of prognostic studies have inherent difficulties, including the possibility of publication bias, the results of the studies in this review show that BNP is a strong prognostic indicator for both asymptomatic patients and for patients with heart failure at all stages of disease.

Original languageEnglish
Pages (from-to)625-627
Number of pages5
JournalBritish Medical Journal
Volume330
Issue number7492
DOIs
Publication statusPublished - 19 Mar 2005
Externally publishedYes

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Publication Bias
Sudden Death
Stroke Volume

Cite this

@article{41beea9e62434b93b622dac42319a1e6,
title = "How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review",
abstract = "OBJECTIVE: To assess how well B-type natriuretic peptide (BNP) predicts prognosis in patients with heart failure.DESIGN: Systematic review of studies assessing BNP for prognosis in patients with heart failure or asymptomatic patients.DATA SOURCES: Electronic searches of Medline and Embase from January 1994 to March 2004 and reference lists of included studies.STUDY SELECTION AND DATA EXTRACTION: We included all studies that estimated the relation between BNP measurement and the risk of death, cardiac death, sudden death, or cardiovascular event in patients with heart failure or asymptomatic patients, including initial values and changes in values in response to treatment. Multivariable models that included both BNP and left ventricular ejection fraction as predictors were used to compare the prognostic value of each variable. Two reviewers independently selected studies and extracted data.DATA SYNTHESIS: 19 studies used BNP to estimate the relative risk of death or cardiovascular events in heart failure patients and five studies in asymptomatic patients. In heart failure patients, each 100 pg/ml increase was associated with a 35{\%} increase in the relative risk of death. BNP was used in 35 multivariable models of prognosis. In nine of the models, it was the only variable to reach significance-that is, other variables contained no prognostic information beyond that of BNP. Even allowing for the scale of the variables, it seems to be a strong indicator of risk.CONCLUSION: Although systematic reviews of prognostic studies have inherent difficulties, including the possibility of publication bias, the results of the studies in this review show that BNP is a strong prognostic indicator for both asymptomatic patients and for patients with heart failure at all stages of disease.",
author = "Doust, {Jenny A} and Eva Pietrzak and Annette Dobson and Paul Glasziou",
year = "2005",
month = "3",
day = "19",
doi = "10.1136/bmj.330.7492.625",
language = "English",
volume = "330",
pages = "625--627",
journal = "BMJ (Clinical research ed.)",
issn = "0959-535X",
publisher = "BMJ Publishing Group",
number = "7492",

}

How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure : Systematic review. / Doust, Jenny A; Pietrzak, Eva; Dobson, Annette; Glasziou, Paul.

In: British Medical Journal, Vol. 330, No. 7492, 19.03.2005, p. 625-627.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure

T2 - Systematic review

AU - Doust, Jenny A

AU - Pietrzak, Eva

AU - Dobson, Annette

AU - Glasziou, Paul

PY - 2005/3/19

Y1 - 2005/3/19

N2 - OBJECTIVE: To assess how well B-type natriuretic peptide (BNP) predicts prognosis in patients with heart failure.DESIGN: Systematic review of studies assessing BNP for prognosis in patients with heart failure or asymptomatic patients.DATA SOURCES: Electronic searches of Medline and Embase from January 1994 to March 2004 and reference lists of included studies.STUDY SELECTION AND DATA EXTRACTION: We included all studies that estimated the relation between BNP measurement and the risk of death, cardiac death, sudden death, or cardiovascular event in patients with heart failure or asymptomatic patients, including initial values and changes in values in response to treatment. Multivariable models that included both BNP and left ventricular ejection fraction as predictors were used to compare the prognostic value of each variable. Two reviewers independently selected studies and extracted data.DATA SYNTHESIS: 19 studies used BNP to estimate the relative risk of death or cardiovascular events in heart failure patients and five studies in asymptomatic patients. In heart failure patients, each 100 pg/ml increase was associated with a 35% increase in the relative risk of death. BNP was used in 35 multivariable models of prognosis. In nine of the models, it was the only variable to reach significance-that is, other variables contained no prognostic information beyond that of BNP. Even allowing for the scale of the variables, it seems to be a strong indicator of risk.CONCLUSION: Although systematic reviews of prognostic studies have inherent difficulties, including the possibility of publication bias, the results of the studies in this review show that BNP is a strong prognostic indicator for both asymptomatic patients and for patients with heart failure at all stages of disease.

AB - OBJECTIVE: To assess how well B-type natriuretic peptide (BNP) predicts prognosis in patients with heart failure.DESIGN: Systematic review of studies assessing BNP for prognosis in patients with heart failure or asymptomatic patients.DATA SOURCES: Electronic searches of Medline and Embase from January 1994 to March 2004 and reference lists of included studies.STUDY SELECTION AND DATA EXTRACTION: We included all studies that estimated the relation between BNP measurement and the risk of death, cardiac death, sudden death, or cardiovascular event in patients with heart failure or asymptomatic patients, including initial values and changes in values in response to treatment. Multivariable models that included both BNP and left ventricular ejection fraction as predictors were used to compare the prognostic value of each variable. Two reviewers independently selected studies and extracted data.DATA SYNTHESIS: 19 studies used BNP to estimate the relative risk of death or cardiovascular events in heart failure patients and five studies in asymptomatic patients. In heart failure patients, each 100 pg/ml increase was associated with a 35% increase in the relative risk of death. BNP was used in 35 multivariable models of prognosis. In nine of the models, it was the only variable to reach significance-that is, other variables contained no prognostic information beyond that of BNP. Even allowing for the scale of the variables, it seems to be a strong indicator of risk.CONCLUSION: Although systematic reviews of prognostic studies have inherent difficulties, including the possibility of publication bias, the results of the studies in this review show that BNP is a strong prognostic indicator for both asymptomatic patients and for patients with heart failure at all stages of disease.

UR - https://www.ncbi.nlm.nih.gov/pubmed/15774989

U2 - 10.1136/bmj.330.7492.625

DO - 10.1136/bmj.330.7492.625

M3 - Review article

VL - 330

SP - 625

EP - 627

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

SN - 0959-535X

IS - 7492

ER -